Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences trodelvy intangible asset — Accumulated amortization ($M) ($M)
Form 10-Q / 10-K Note 9
Latest, Q2 2026
4,704
Period ended Jun 30, 2026
Change on a year earlier
+29.8%
3,623 in Q2 2025
History
22 quarters
Since Q4 2020
Sources
21
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trodelvy intangible asset — Accumulated amortization ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 4,704 | +29.8% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 4,434 | +32.2% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 4,164 | +35.1% | Form 10-Q (filed 2026-08-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 3,894 | +38.4% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 3,623 | +42.5% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 3,353 | +47.6% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 3,083 | +54.0% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,813 | +62.4% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,543 | +73.9% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 2,272 | +90.6% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 2,002 | +105.8% | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,732 | +102.3% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,462 | +97.6% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,192 | +91.3% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 973 | +91.9% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 856 | +119.5% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 740 | +170.1% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 623 | – | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 507 | +704.8% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2021 | Sep 30, 2021 | 390 | – | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 274 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 63 | – | Form 10-K (filed 2022-02-23) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Trodelvy intangible asset — Accumulated amortization ($M) ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/intang_trodelvy_accum
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.